Our CMC Connect team in the UK took home the ‘Highly Commended’ award at the prestigious 2018 Pharmaceutical Market Excellence Awards (PMEA), designed to recognise excellence and innovation in improving patient outcomes. The commendation was awarded in the category ‘Excellence in Healthcare Professional Education and Support Programs’ for the work of CMC Connect with AstraZeneca on their immuno-oncology safety masterclasses.

The aim of this ongoing initiative is to improve levels of expertise and confidence amongst healthcare professionals (HCPs), ensuring patient safety and commercial success. Between January 2017 and June 2018, 23 ‘live’ masterclass meetings have been executed, reaching 483 HCPs across 15 countries. During the program, CMC Connect demonstrated a significant shift in HCP confidence levels and steep advances in overall expertise.

Judge’s comment:

“AstraZeneca and CMC’s campaign had a remarkable reach and scale. It had an impressive impact on mortality rates and demonstrated correlation between the before and after effect. It is a novel approach to improving knowledge around clinical trials.”

Kirsten Parr, Head of CMC Connect, commented:

Huge congratulations to everyone involved in this project! It’s fantastic to see it getting this recognition which is very well deserved!

Also, CMC Connect’s other entry was selected as a finalist at PMEA.

  • FASENRA (a biologic therapy for severe asthma) by CMC Connect: category ‘Excellence in Capability Development.’

Judge’s comment:

“CMC demonstrated good metrics and a clear strategy. They have a strong staff retention rate, with a clear development plan, which resulted in high satisfaction scores from their team. After 25 years, CMC are still clearly ambitious, and this stood out in their entry.”

Congratulations to all involved!

View All Insight Posts